Flow cytometric analysis of mouse CD96 expression on C57BL/6 mouse splenocytes. C57BL/6 mouse splenocytes were stained with Brilliant Violet 421™ Rat Anti-Mouse CD3 Antibody and either Biotin Rat IgG1, λ Isotype Control (left panel) or SDT Biotin Rat Anti- Mouse CD96 Antibody (right panel) at 2 μl/test followed by Sav-PE. Total viable cells, as determined by Fixable Viability Dye 515 (S0D0013), were used for analysis. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Biotin Rat Anti-Mouse CD96 Antibody (3.3)
Biotin Rat Anti-Mouse CD96 Antibody (3.3)
Price:
Regular price
$85 USD
Regular price
Sale price
$85 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | CD96 |
| Synonyms | T-cell surface protein tactile; Cell surface antigen CD96; T cell-activated increased late expression protein; Cd96 |
| Location | Membrane |
| Accession | Q3U0X8 |
| Clone Number | 3.3 |
| Antibody Type | Rat mAb |
| Isotype | IgG1,λ |
| Application | FCM |
| Reactivity | Ms |
| Positive Sample | C57BL/6 mouse splenocytes |
| Purification | Protein G |
| Concentration | 0.5 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 30 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1μg per million cells in 100μl volume | Ms |
Background
CD96, also known as TACTILE (T cell activation, increased late expression), is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily, encoded by the CD96 gene. It is primarily expressed on T cells and natural killer (NK) cells, and is involved in immune regulation. CD96 shares sequence similarity with CD226 (DNAM-1) and competes with it for binding to CD155, its main ligand. This interaction can inhibit NK cell function and cytokine responses, making CD96 a potential target for cancer immunotherapy. Research has shown that blocking CD96 can enhance antitumor immunity, particularly when combined with other treatments such as anti-PD-1 or anti-CTLA-4 therapies. Additionally, CD96 expression is associated with immune infiltration and poor clinical outcomes in some cancers, further highlighting its potential as a therapeutic target.
Picture
Picture
FC
